Table 1 Change in HDL-c and HDL subclass in breast cancer patients
From: Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
Study | Patient enrolled | High Density Lipoproteins |
|---|---|---|
[134] | N = 48 early-stage cancerous breast tumour patients N = 40 non-cancerous breast tumour patients | ↓ HDL-c in breast cancer patients vs. non-cancerous patients |
[135] | N = 83 breast cancer patients (Stage I-IV) N = 83 healthy patients | ↓ HDL-c in Stage IV breast cancer patients vs. healthy patients |
[136] | N = 58 breast cancer patients N = 105 healthy patients | No change in HDL-c vs. healthy patients |
[132] | N = 30 breast cancer patients N = 30 healthy patients | ↓ HDL-c, HDL2 and HDL3 vs. healthy patients, an effect more pronounced for HDL-2 (-41%) than HDL-3 (-8%) |
[131] | N = 56 postmenopausal breast cancer patients (Stage II-IV) N = 44 healthy patients | ↓ HDL-c, HDL2 and HDL3 vs. healthy patients Furthermore, advancement of disease affects lipid profile where, ↓ HDL-c in Stage IV breast cancer patients vs. Stage II breast cancer patients |
[137] | N = 90 breast cancer patients N = 103 healthy patients | ↓ HDL-c in breast cancer patients vs. healthy patients |
[138] | N = 100 breast cancer patients (Stage I-IV) N = 50 healthy patients | No change in HDL-c in breast cancer patients vs. healthy patients |
[139] | N = 17 postmenopausal breast cancer patients N = 30 postmenopausal healthy patients | No change in HDL-c in breast cancer patients vs. healthy patients |
[128] | N = 125 breast cancer patients (Stage I -IV) N = 70 healthy patients | ↓ HDL-c breast cancer patients vs. healthy patients |
[140] | N = 100 pre- and postmenopausal breast cancer patients N = 100 healthy patients | No change in HDL-c in breast cancer patients vs. healthy patients |
[127] | N = 120 breast cancer patients N = 60 healthy patient | No change in HDL-c vs. healthy patients |
[141] | N = 60 pre- and postmenopausal breast cancer patients N = 60 healthy patients | No change in HDL-c vs. healthy patients |
[142] | N = 249 early stage breast cancer patients N = 154 healthy patients | ↓ HDL-c in breast cancer patients ≤ 50 years old vs. healthy patients ↑ HDL-c in breast cancer patients ≥ 50 years old vs. healthy patients |
[133] | N = 56 breast cancer patients (Stage I-II) No healthy patients included as controls | Large HDL subfractions associated with breast tumours expressing the progesterone receptor |
[143] | N = 150 breast cancer patients N = 75 healthy patients | Unchanged HDL-c vs. healthy patients |
[144] | N = 1054 breast cancer patients N = 2483 healthy patients | ↓ HDL-c in breast cancer patients < 60 years old vs. healthy patients Unchanged HDL-c in breast cancer patients > 60 years old vs. healthy patients |